

Certificate of Analysis for NR-59473

Polyclonal Anti-Influenza A Virus H3 Hemagglutinin (HA), A/Darwin/9/2021 (H3N2) (antiserum, Goat)

Catalog No. NR-59473

This reagent is the property of the U.S. Government.

Product Description:

Antiserum to the H3 hemagglutinin (HA) from influenza virus was produced by serial immunization of a goat with recombinant baculovirus-expressed H3 HA protein derived from A/Darwin/9/2021 (H3N2) influenza virus. This item was manufactured and subjected to quality control testing by St. Jude Children's Research Hospital (SJCRH), Memphis, Tennessee, USA.

Lot: 70065116 Manufacturing Date: 22JAN2024

TEST	SPECIFICATIONS	RESULTS
Functional Activity ^{1,2}		
Hemagglutinin inhibition (HI) titer with homologous virus A/Darwin/9/2021 (H3N2) (H3N2)	Report results	1:1280
HI assay with antigens representing 16 HA subtypes	Specific to H3 HA subtype	Specific to H3 HA subtype
HI titers with H3 influenza virus		
A/Perth/16/2009 (H3N2)	Report results	1:320
A/Victoria/210/2009 (H3N2)	Report results	1:1280
A/Texas/50/2012 (H3N2)	Report results	1:640
A/Hong Kong/5738/2014 (H3N2)	Report results	1:2560
A/Hong Kong/2286/2017 (H3N2)	Report results	1:2560
A/Switzerland/8060/2017 (H3N2)	Report results	1:2560
Sterility	Report results	Low bioburden

¹HI assays were performed with 0.5% turkey red blood cells.

/Sonia Bjorum Brower/ Sonia Bjorum Brower

12 APR 2024

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by the contractor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org Tel: 800-359-7370

Fax: 703-365-2898

²Treatment with receptor-destroying enzyme (RDE; Denka Seiken Co., LTD) at 37°C overnight, followed by heat-inactivation at 56°C for 1 hour, is needed to remove non-specific inhibitors of hemagglutination.